Cytogen completes merger of wholly owned unit GenomeCare

• Cytogen completed the merger of wholly owned subsidiary GenomeCare on Oct. 1, 2026.
• The deal used a 1:0 merger ratio, issuing no new shares and leaving major shareholder stakes unchanged.
• Opposition notices came from 963 shareholders covering 236,678 shares, equal to 1.02% of shares outstanding.
• No creditor objections were filed during the Aug. 31 to Sept. 30 period.
• Pro forma balance sheet at June 30, 2026 showed combined assets of 52,527,571,847 won, liabilities of 20,335,093,013 won.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytogen Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001000367), on October 01, 2026, and is solely responsible for the information contained therein.